U.S. Markets close in 1 hr 37 mins

Free Pre-Market Technical Pulse on W.R. Grace and Three More Specialty Chemicals Stocks

Stock Research Monitor: VNTR, WLK, and YTEN

LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on GRA sign up now at www.wallstequities.com/registration. Today, WallStEquities.com takes a look at the recent performance of Venator Materials PLC (NYSE: VNTR), W. R. Grace & Co. (NYSE: GRA), Westlake Chemical Corp. (NYSE: WLK), and Yield10 Bioscience Inc. (NASDAQ: YTEN). These companies are part of the Specialty Chemicals industry, which caters to diverse sectors through innovative products that are essentially tailored to the specific requirements of end markets. These products essentially act as intermediaries to other consumer industries. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Venator Materials

Stockton-On-Tees, the UK headquartered Venator Materials PLC's stock finished Thursday's session 0.27% lower at $18.37 with a total trading volume of 280,037 shares. The stock is trading 1.04% above their 50-day moving average. Shares of the Company, which manufactures and markets chemical products worldwide, have a Relative Strength Index (RSI) of 58.00.

On April 25th, 2018, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock, with a target price of $28 per share.

On May 01st, 2018, Venator Materials reported its first-quarter 2018 results with revenues of $622 million, net income attributable to the Company of $78 million, and adjusted EBITDA of $157 million. Net cash provided by operating activities from continuing operations was $51 million for the quarter, and free cash flow was $(15) million. As of March 31st, 2018, the Company had cash and cash equivalents of $223 million. Get the full research report on VNTR for free by clicking below at:

www.wallstequities.com/registration/?symbol=VNTR


W.R. Grace

On Thursday, shares in Columbia, Maryland headquartered W.R. Grace & Co. recorded a trading volume of 639,613 shares. The stock ended the session 0.77% lower at $72.14. The Company's shares have advanced 4.78% in the last month, 6.53% in the previous three months, and 0.38% over the past year. The stock is trading 7.64% above its 50-day moving average and 2.91% above its 200-day moving average. Moreover, shares of W.R. Grace, which produces and sells specialty chemicals and materials worldwide, have an RSI of 61.98.

On May 09th, 2018, W.R. Grace announced that its Board of Directors has elected Shlomo Yanai as an independent director. Yanai currently is Chairman of the Cambrex Corporation, Chairman of Protalix Biotherapeutics, and a senior advisor to Moelis & Co.

On May 16th, 2018, research firm Jefferies upgraded the Company's stock rating from ‘Hold' to ‘Buy'. Download our actionable research report on GRA at:


www.wallstequities.com/registration/?symbol=GRA


Westlake Chemical

Houston, Texas headquartered Westlake Chemical Corp.'s shares closed the day 0.73% lower at $120.53. The stock recorded a trading volume of 494,648 shares. The Company's shares have gained 12.59% in the last month, 8.40% over the previous three months, and 91.80% over the past year. The stock is trading 7.29% and 21.97% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Westlake Chemical, which manufactures and markets basic chemicals, vinyls, polymers, and building products primarily in North America and Europe, have an RSI of 62.04.

On May 11th, 2018, research firm Cowen reiterated its ‘Outperform' rating on the Company's stock with an increase of the target price from $122 a share to $124 a share.

On May 18th, 2018, Westlake Chemical's Board of Directors declared a regular dividend distribution of $0.2100 per share. The dividend will be payable on June 13th, 2018, to stockholders of record on May 30th, 2018. Register for your free report coverage on WLK at:

www.wallstequities.com/registration/?symbol=WLK


Yield10 Bioscience

Shares in Woburn, Massachusetts headquartered Yield10 Bioscience Inc. finished 2.48% lower at $1.61. The stock recorded a trading volume of 169,675 shares. The Company's shares have advanced 3.81% in the previous three months. The stock is trading below its 50-day moving average by 11.33%. Furthermore, shares of Yield10 Bioscience, which engages in developing disruptive technologies for enhancing crop yield in the US and Canada, have an RSI of 40.99.

On May 22nd, 2018, Yield10 Bioscience announced that it has executed an exclusive worldwide license to two, novel gene technologies to boost oil content in crops from the University of Missouri. The university previously granted the Company a one-year option to evaluate the technologies. Get the free research report on YTEN at:

www.wallstequities.com/registration/?symbol=YTEN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities